---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034556"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:19:08.876580+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win

## Summary
- Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.
- GAAP net income $237.1M ($1.43 basic EPS) vs net loss $30.1M in Q2 2022; non-GAAP net income $94.3M ($0.57 EPS).
- LYBALVI net sales $47.0M (+134% YoY); VIVITROL $102.1M (+6%); ARISTADA $82.4M (+10%).
- Cash and investments $907.2M; FY 2023 financial expectations reiterated, including accretive INVEGA royalties.
- Oncology separation into Mural Oncology on track for H2 2023; Caroline Loew appointed CEO designate.

## SEC filing metadata
- accession: 0000950170-23-034556
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/0000950170-23-034556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/alks-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034556
- JSON: https://secwatch.observer/filing/0000950170-23-034556.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034556.txt

## Key facts
- Earnings Releases
  Alkermes plc. updated its three and six months ended June 30, 2023 guidance (reaffirmed).
  - Period: three and six months ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On July 26, 2023, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/0000950170-23-034556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.